⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9642310 | 0.76 | — | — | |
| SCHEMBL19909691 | 0.72 | — | — | |
| SCHEMBL6253655 | 0.72 | — | — | |
| SCHEMBL27476502 | 0.69 | AKR1C3 (0.30) | — | |
| SCHEMBL19520866 | 0.67 | — | — | |
| SCHEMBL3099642 | 0.67 | — | — | |
| SCHEMBL3099636 | 0.66 | AKR1C3 (0.34) | — | |
| SCHEMBL29039442 | 0.66 | AKR1C3 (0.30) | — | |
| SCHEMBL8403550 | 0.60 | CYP2D6 (0.34) | — | |
| SCHEMBL7423267 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| CN-115279755-A | Compounds, compositions and methods for treating NASH, NAFLD, and obesity | CVI制药有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2021067490-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2021-04-08 | — | — | WO | disclosed |
| EP-2370434-B1 | ISOQUINOLINYL-CONTAINING ALKALOID COMPOUNDS AND COMPOSITIONS USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LTD (KY) | 2014-09-17 | — | — | EP | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| US-20110269754-A1 | COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2011-11-03 | — | — | US | disclosed |
| EP-2370434-A1 | CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS | CVI Pharmaceuticals Limited (KY) | 2011-10-05 | — | — | EP | disclosed |
| US-8003795-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2011-08-23 | — | — | US | disclosed |
| WO-2010075469-A1 | CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2010-07-01 | — | — | WO | disclosed |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002873-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2008-12-31 | — | — | WO | disclosed |